1227 GMT - GSK is unlikely to take a financial hit from litigation with AnaptysBio over the Jemperli license, J.P. Morgan analysts write. The U.K. drugmaker's cancer treatment accounts for only about 1% of its net present value in their model, the analysts say. GSK already boosted the royalties it pays to the U.S. biotech group in a 2020 settlement to what is a fair, attractive level, the analysts write. More details from the court case will be needed to fully assess the outcome, they add. Shares are up 0.2% at 1,764.5 pence and up 31% year-to-date. (william.gray@wsj.com)

(END) Dow Jones Newswires

November 21, 2025 07:28 ET (12:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.